ACB
Price
$5.62
Change
+$0.29 (+5.44%)
Updated
Aug 28 closing price
Capitalization
315.11M
69 days until earnings call
MEDIF
Price
$0.06
Change
-$0.00 (-0.00%)
Updated
Aug 28 closing price
Capitalization
22.81M
Interact to see
Advertisement

ACB vs MEDIF

Header iconACB vs MEDIF Comparison
Open Charts ACB vs MEDIFBanner chart's image
Aurora Cannabis
Price$5.62
Change+$0.29 (+5.44%)
Volume$2.37M
Capitalization315.11M
Medipharm Labs
Price$0.06
Change-$0.00 (-0.00%)
Volume$351.37K
Capitalization22.81M
ACB vs MEDIF Comparison Chart in %
Loading...
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEDIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACB vs. MEDIF commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a StrongBuy and MEDIF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (ACB: $5.62 vs. MEDIF: $0.06)
Brand notoriety: ACB: Notable vs. MEDIF: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ACB: 155% vs. MEDIF: 274%
Market capitalization -- ACB: $315.11M vs. MEDIF: $22.81M
ACB [@Pharmaceuticals: Generic] is valued at $315.11M. MEDIF’s [@Pharmaceuticals: Generic] market capitalization is $22.81M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.6B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACB’s FA Score shows that 0 FA rating(s) are green whileMEDIF’s FA Score has 0 green FA rating(s).

  • ACB’s FA Score: 0 green, 5 red.
  • MEDIF’s FA Score: 0 green, 5 red.
According to our system of comparison, MEDIF is a better buy in the long-term than ACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACB’s TA Score shows that 6 TA indicator(s) are bullish while MEDIF’s TA Score has 3 bullish TA indicator(s).

  • ACB’s TA Score: 6 bullish, 5 bearish.
  • MEDIF’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, ACB is a better buy in the short-term than MEDIF.

Price Growth

ACB (@Pharmaceuticals: Generic) experienced а +17.57% price change this week, while MEDIF (@Pharmaceuticals: Generic) price change was +4.18% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.15%. For the same industry, the average monthly price growth was +68.06%, and the average quarterly price growth was +81.85%.

Reported Earning Dates

ACB is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.15% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACB($315M) has a higher market cap than MEDIF($22.8M). MEDIF YTD gains are higher at: 38.741 vs. ACB (32.235). ACB has higher annual earnings (EBITDA): 26.6M vs. MEDIF (-4.75M). ACB has more cash in the bank: 140M vs. MEDIF (8.44M). MEDIF has less debt than ACB: MEDIF (125K) vs ACB (102M). ACB has higher revenues than MEDIF: ACB (358M) vs MEDIF (43M).
ACBMEDIFACB / MEDIF
Capitalization315M22.8M1,382%
EBITDA26.6M-4.75M-560%
Gain YTD32.23538.74183%
P/E Ratio19.44N/A-
Revenue358M43M833%
Total Cash140M8.44M1,658%
Total Debt102M125K81,600%
FUNDAMENTALS RATINGS
ACB vs MEDIF: Fundamental Ratings
ACB
MEDIF
OUTLOOK RATING
1..100
2775
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
91
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5448
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACB's Valuation (59) in the Pharmaceuticals Other industry is in the same range as MEDIF (91) in the null industry. This means that ACB’s stock grew similarly to MEDIF’s over the last 12 months.

ACB's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as MEDIF (100) in the null industry. This means that ACB’s stock grew similarly to MEDIF’s over the last 12 months.

ACB's SMR Rating (100) in the Pharmaceuticals Other industry is in the same range as MEDIF (100) in the null industry. This means that ACB’s stock grew similarly to MEDIF’s over the last 12 months.

MEDIF's Price Growth Rating (48) in the null industry is in the same range as ACB (54) in the Pharmaceuticals Other industry. This means that MEDIF’s stock grew similarly to ACB’s over the last 12 months.

MEDIF's P/E Growth Rating (100) in the null industry is in the same range as ACB (100) in the Pharmaceuticals Other industry. This means that MEDIF’s stock grew similarly to ACB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACBMEDIF
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 25 days ago
84%
Declines
ODDS (%)
Bearish Trend 10 days ago
88%
Bearish Trend 15 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
54%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEDIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AFSIC16.050.30
+1.90%
AmTrust Financial Services, Inc.
SWRAY8.670.04
+0.46%
Swire Pacific Ltd.
ANZLY1.65N/A
N/A
Air New Zealand Ltd.
PGXPF0.11N/A
N/A
Pelangio Exploration Inc.
COOSF11.60N/A
N/A
Carbios SA

ACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACB has been loosely correlated with SNDL. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if ACB jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACB
1D Price
Change %
ACB100%
+5.44%
SNDL - ACB
65%
Loosely correlated
+6.32%
CGC - ACB
64%
Loosely correlated
+24.50%
OGI - ACB
63%
Loosely correlated
+3.59%
CRON - ACB
55%
Loosely correlated
+1.56%
TLRY - ACB
54%
Loosely correlated
+7.30%
More

MEDIF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MEDIF has been loosely correlated with CGC. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if MEDIF jumps, then CGC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEDIF
1D Price
Change %
MEDIF100%
+2.87%
CGC - MEDIF
36%
Loosely correlated
+24.50%
TLRY - MEDIF
28%
Poorly correlated
+7.30%
ACB - MEDIF
24%
Poorly correlated
+5.44%
AAWH - MEDIF
24%
Poorly correlated
+0.65%
GLASF - MEDIF
24%
Poorly correlated
+1.08%
More